Login Register Cart 0
Generic placeholder image

Current Biotechnology

Editor-in-Chief

ISSN (Print): 2211-5501
ISSN (Online): 2211-551X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Brief Overview of Invasive Fungal Infections in Immunocompromised Individuals

Author(s): Deepak Kakasaheb Pisote*, Gowtham Menon and Rohit Lahurao Choure

Volume 11, Issue 2, 2022

Published on: 19 September, 2022

Page: [117 - 122] Pages: 6

DOI: 10.2174/2211550111666220802162126

Price: $65

Abstract

Fungí is eukaryotic microorganisms that may spread and cause illness on the skin, subcutaneously, and systemically. These infections can be invasive and difficult to identify at times. A patient with a damaged immune system is more likely to get a fungal infection. Long-term chemotherapy, organ transplantation, corticosteroid usage, or multidrug treatment all result in immunocompromised people. Why do immunocompromised individuals need to be treated? The answer of this query is that the immune system serves as an army for the human body, if it fails to protect it, foreign particles such as bacteria, fungus, and viruses assault the body, causing the patient to become immunocompromised. Candidiasis, aspergillosis, mucormycosis, and cryptococcal meningitis are the most frequent invasive fungal diseases encountered in immunocompromised people. Patients afflicted with invasive fungal infections have a significant death rate. As the number of immunocompromised patients rises, so does the number of fungal infections. In this article, we took a quick look at a few invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis.

Keywords: Immunocompromised patients, Candidiasis, Aspergillosis, Mucormycosis, Amphotericin B, invasive fungal infections.

« Previous Next »
Graphical Abstract

[1]
McGinnis MR, Tyring SK. Introduction to Mycology. In: Baron S., Ed. Medical Microbiology. 4th edition. Amsterdam, Netherlands: Elsevier, 1996; pp. 925-8.
[http://dx.doi.org/10.1128/9781555817497.part6] [PMID: 21413300]
[2]
Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: Diagnosis & clinical management. Indian J Med Res 2014; 139(2): 195-204.
[3]
Rodriguesid ML, Nosanchuk JD. Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl Trop Dis 2020; 14(2): e0007964.
[http://dx.doi.org/10.1371/journal.pntd.0007964]
[4]
Meidani M, Naeini AE, Rostami M, Sherkat R, Tayeri K. Immunocompromised patients: Review of the most common infections happened in 446 hospitalized patients. J Res Med Sci 2014; 19 (Suppl. 1): S71-3.
[5]
Ravikumar S, Win MS, Chai LY. Optimizing outcomes in immunocompromised hosts: Understanding the role of im-munotherapy in invasive fungal diseases. Front Microbiol 2015; 6: 1322.
[http://dx.doi.org/10.3389/fmicb.2015.01322] [PMID: 26635780]
[6]
Macintyre AT, Hirst A, Duttagupta R, Hollemon D, Hong DK, Blauwkamp TA. Budget impact of microbial cell-free DNA testing using the Karius® test as an alternative to invasive pro-cedures in immunocompromised patients with suspected in-vasive fungal infections. Appl Health Econ Health Policy 2021; 19: 231-41.
[http://dx.doi.org/10.1007/s40258-020-00611-7]
[7]
Pfavayi LT, Denning DW, Baker S, Sibanda EN, Mutapi F. Determining the burden of fungal infections in Zimbabwe. Sci Rep 2021; 11: 13240.
[http://dx.doi.org/10.1038/s41598-021-92605-1]
[8]
Ayan NR, Rafiq NB. Candidiasis. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560624/
[9]
Spampinato C, Leonardi D. Candida infections, causes, tar-gets, and resistance mechanisms: Traditional and alternative antifungal agents. BioMed Res Int 2013; 2013: 204237.
[http://dx.doi.org/10.1155/2013/204237] [PMID: 23878798]
[10]
de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, et al. Candida infections and therapeutic strategies: Mechanisms of action for traditional and alternative agents. Front Microbiol 2018; 9: 1351.
[http://dx.doi.org/10.3389/fmicb.2018.01351] [PMID: 30018595]
[11]
Taylor M, Raja A. Oral candidiasis. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www. ncbi. nlm.nih.gov/books/NBK545282/
[12]
Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of oral candida infection and therapeutic strategies. Front Microbiol 2015; 6: 1391.
[http://dx.doi.org/10.3389/fmicb.2015.01391] [PMID: 26733948]
[13]
Hughes JM, Remington JS. Systemic candidiasis, a diagnostic challenge. California Medicine 1972; 116: 8.
[14]
Pilmis B, Yang Z, Lanternier F, Lortholary O. Systemic can-didiasis. Infect Dis 2017; 1: 439-445.e1.
[http://dx.doi.org/10.1016/B978-0-7020-6285-8.00049-6]
[15]
Palese E, Nudo M, Zino G, et al. Cutaneous candidiasis caused by Candida albicans in a young non-immunosuppressed patient: An unusual presentation. Int J Immunopathol Pharmacol 2018; 32: 2058738418781368.
[http://dx.doi.org/10.1177/2058738418781368] [PMID: 29882446]
[16]
Kühbacher A, Burger-Kentischer A, Rupp S. Interaction of candida species with the skin. Microorganisms 2017; 5(2): E32.
[http://dx.doi.org/10.3390/microorganisms5020032] [PMID: 28590443]
[17]
Samanta P, Hong Nguyen M. Pathogenesis of invasive pul-monary aspergillosis in transplant recipients. Current Fungal Infection Reports 11: 148-57.
[http://dx.doi.org/10.1007/s12281-017-0278-5]
[18]
Vuong MF, Waymack JR. Aspergillosis. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi. nlm.nih.gov/books/NBK482241/
[19]
Kohno S, Kobayashi T, Kakeya H, Miyazaki Y. Pulmonary aspergillosis: Diagnosis and treatment. Kekkaku 2016; 78(12): 167-83.
[http://dx.doi.org/10.1016/B978-0-12-804543-5.00012-9]
[20]
Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: Aspergillosis clinical review. Eur Respir Rev 2011; 20(121): 156-74.
[http://dx.doi.org/10.1183/09059180.00001011] [PMID: 21881144]
[21]
Rudramurthy S M, Paul R A, Chakrabarti A, Mouton J W, Meis J F. Invasive aspergillosis by Aspergillus flavus: Epidemiology, diagnosis, antifungal resistance, and management
[http://dx.doi.org/10.3390/jof5030055]
[22]
Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumiga-tus in invasive aspergillosis. Clin Microbiol Rev 2009; 22(3): 447-65.
[http://dx.doi.org/10.1128/CMR.00055-08] [PMID: 19597008]
[23]
Steinbach WJ. Aspergillosis. In: Steinbach WJ, Green MD, Michaels MG, Fisher BT, Danziger-Isakov LA, Eds. Pediatric transplant and oncology infectious diseases; Amseterdam, nethelands: Elsevier, 2021; pp. 170-180.e3.
[http://dx.doi.org/10.1016/B978-0-323-64198-2.00033-6]
[24]
Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic pulmonary aspergillosis. Mycoses 2014; 57(5): 257-70.
[http://dx.doi.org/10.1111/myc.12152] [PMID: 24299422]
[25]
Izumikawa K. Recent advances in chronic pulmonary asper-gillosis. Respir Investig 2016; 54(2): 85-91.
[http://dx.doi.org/10.1016/j.resinv.2015.10.003] [PMID: 26879477]
[26]
Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47(1): 45-68.
[http://dx.doi.org/10.1183/13993003.00583-2015] [PMID: 26699723]
[27]
Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Treating allergic bronchopulmonary aspergillosis: A review. Cureus 2019; 11(4): e4538.
[http://dx.doi.org/10.7759/cureus.4538] [PMID: 31263646]
[28]
Sisodia J, Bajaj T. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542329/
[29]
Sunman B, Ademhan Tural D, Ozsezen B, Emiralioglu N, Yalcin E, Özçelik U. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Front Pediatr 2020; 8: 582964.
[http://dx.doi.org/10.3389/fped.2020.582964] [PMID: 33194914]
[30]
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel) 2020; 6: 265.
[http://dx.doi.org/10.3390/jof6040265]
[31]
Binder U, Maurer E, Lass-Flörl C. Mucormycosis--from the pathogens to the disease. Clin Microbiol Infect 2014; 20: 60-6.
[http://dx.doi.org/10.1111/1469-0691.12566]
[32]
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and manage-ment. Clin Microbiol Rev 2005; 18(3): 556-69.
[http://dx.doi.org/10.1128/CMR.18.3.556-569.2005] [PMID: 16020690]
[33]
Low CY, Rotstein C. Emerging fungal infections in immuno-compromised patients. F1000 Med Rep 2011; 3(1): 14.
[http://dx.doi.org/10.3410/M3-14] [PMID: 21876720]
[34]
Noor A, Preuss Cv. Amphotericin B. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi. nlm.nih.gov/books/NBK482327/
[35]
Waugh CD, Amphotericin B. In: Enna SJ, Bylund DB, Eds xPharm: Comprehensive Pharmacology Reference; Amsterdam, The Netherlands: Elsevier 2007; pp. 1-5.
[http://dx.doi.org/10.1016/B978-008055232-3.61226-7]
[36]
Pasko MT, Piscitelli SC, Van Slooten AD. Fluconazole: A new triazole antifungal agent. DICP 1990; 24(9): 860-7.
[http://dx.doi.org/10.1177/106002809002400914] [PMID: 2260347]
[37]
Greer ND. Voriconazole: The newest triazole antifungal agent. Proc Bayl Univ Med Cent 2003; 16(2): 241-8.
[http://dx.doi.org/10.1080/08998280.2003.11927910] [PMID: 16278744]
[38]
Gullo A. Invasive fungal infections. Drugs 2012; 69: 65-73.
[http://dx.doi.org/10.2165/11315530-000000000-00000]
[39]
Vermes A, Guchelaar HJ, Dankert J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, tox-icity and drug interactions. J Antimicrob Chemother 2000; 46(2): 171-9.
[http://dx.doi.org/10.1093/jac/46.2.171] [PMID: 10933638]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy